

18. A compound of the formula  $R_1-X-R_2$ , wherein:

$R_1$  and  $R_2$  are each a tumor necrosis factor (TNF) inhibitor polypeptide selected from:

(a) 30 kDa TNF inhibitor or 40 kDa TNF inhibitor,

(b) 30 kDa TNF inhibitor or 40 kDa TNF inhibitor, modified to contain at least one non-native cysteine residue, and

(c) a biologically active portion of (a) or (b), wherein  $R_1$  and  $R_2$  bind to TNF; and

$X$  is a non-peptidic polymer defined as  $-Y_1-(Z)_n-Y_2-$ , wherein  $Y_1$  and  $Y_2$  represent residues of activating groups and  $(Z)_n$  represents a base polymeric group, wherein  $(Z)_n$  is [having two activated groups linked thereto, said non-peptidic polymer being] selected from polyethylene glycol, polypropylene glycol, polyoxyethylated glycerol [and other polyoxyethylated polyols, polyvinyl alcohol and other polyalkylene oxides, polyoxyethylated sorbitol or polyoxyethylated glucose], dextran, colonic acids, poly  $\beta$ -amino acids or carbohydrate polymers.

### Remarks

Claim 15 has been amended. This application incorporates by reference U.S. Patent Application Serial No. 07/850,675, filed March 13, 1992, which is a continuation-in-part of abandoned U.S. Patent Application Serial No. 07/669,862, filed March 15, 1991, which is a continuation-in-part of abandoned U.S. Patent Application Serial No. 07/555,274, filed July 19, 1990 and a continuation-in-part of U.S. Patent No. 5,075,222, issued December 24, 1991 (see e.g., the present specification at Page 1, first paragraph). The present claims are entitled to the benefit of priority of at least U.S. Patent Application Serial Nos. 07/669,862 and 07/850,675. Support for Claim 15 may be found, for example, in Page 30, line 16 to Page 31, line 23 of 07/850,675. Accordingly, the claim amendments do not add new matter.

### Discussion

At the outset, Applicants gratefully acknowledge the Examiner having withdrawn the previous rejection of Claim 15 under 35 U.S.C. 112, first and second paragraph and the previous rejection of Claims 15, 17-19, 22, 31-33 and 44 under U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Shaw *et al.*

### Rejection of Claims 15 and 45-58 under 35 U.S.C. §112, first paragraph

Claims 15 and 45-58 stand rejected under 35 U.S.C. §112, first paragraph, as being non-enabled by the specification.

The Office states that the "Applicant is required to indicate support for each and every element alone as well as in combination with each other which includes the non-peptidic polymers ...".